Menu Search
Equities

Outlook Therapeutics Inc

41O:MUN

Outlook Therapeutics Inc

Actions
  • Price (EUR)4.88
  • Today's Change-0.06 / -1.21%
  • Shares traded2.00k
  • 1 Year change-39.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Outlook Therapeutics Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 66.05m to a smaller loss of 58.98m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-205.48%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Outlook Therapeutics Inc increased its cash reserves by 34.46%, or 6.00m. Cash Flow from Financing totalled 48.97m or -- of revenues. In addition the company used 42.97m for operations while cash used for investing totalled .
Cash flow per share-5.71
Price/Cash flow per share--
Book value per share-3.57
Tangible book value per share-3.57
More ▼

Balance sheet in USDView more

Outlook Therapeutics Inc uses little or no debt in its capital structure.
Current ratio1.07
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.